| Property | Detail |
|---|---|
| Epitope Type | Carbohydrate (globo-series glycosphingolipid) |
| Key Sequence | Fucα1-2Galβ1-3GalNAcβ1-3Gal |
| Tissue Distribution | Normal mammary epithelium; carcinomas of breast, ovary, lung, prostate |
| Diagnostic Utility | Detects micrometastases in bone marrow and lymph nodes |
MBr1 binds to glycoconjugates (glycolipids, glycoproteins, mucins) on cancer cells . This interaction enables:
Immunohistochemical detection of tumor cells in formalin-fixed tissues .
Complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) in therapeutic contexts .
In a study of 121 breast cancer patients, MBr1 detected micrometastases in 16.5% of bone marrow samples missed by conventional histology .
MBr1 positivity correlated with tumor aggressiveness and reduced survival in breast and small-cell lung cancer .
A chimeric mouse-human variant (γICHI-MBr1) retained tumor-binding specificity while enhancing ADCC and complement activation .
Clinical trials administering MBr1 (up to 16 mg) reported no severe toxicity, with transient side effects (fever, abdominal pain) at higher doses .
| Format | Specificity | ADCC Activity | Clinical Use |
|---|---|---|---|
| Murine IgM (native) | High | Low | Diagnostics |
| Chimeric IgG1 | High | High | Therapeutics |